MedPath

Clinical study of acupuncture on treating chemotherapy induced peripheral neuropathy

Not Applicable
Recruiting
Conditions
chemotherapy induced peripheral neuropathy
Registration Number
ITMCTR2100004778
Lead Sponsor
Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

1.Patients with tumors diagnosed by pathological cytology or histology;
2.There were numbness, hypoesthesia, pain and paresthesia in extremities after chemotherapy with platinum or taxanes. Some patients have muscle spasm, muscle weakness, myalgia, and even paralysis;
3.Peripheral neuropathy of grade 1 or above according to NCI adverse reaction evaluation criteria within 7 days to 2 years after stopping chemotherapy;
4.The main TCM syndrome is qi deficiency and blood stasis;
5.The Eastern Oncology Cooperative Group (EOCG) score is 0-3;
6.The expected survival time is more than 3 months.

Exclusion Criteria

1.Patients receiving other medications that may cause neurotoxicity;
2.Receive any drugs that are suspected to be effective, such as tricyclic antidepressants or anticonvulsants;
3.Patients with severe heart, liver, kidney, immune and hematopoietic system diseases;
4.Pregnant women and lactating women;
5.Patients are fear of acupuncture, allergy to stainless steel needle and other reasons can not accept acupuncture treatment.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Classification of NCI-CTCAE peripheral neuropathy;
Secondary Outcome Measures
NameTimeMethod
Digital pain grading score;Score of EORTC QLQ-CIPN20 Scale;syndrome of qi deficiency and blood stasis;
© Copyright 2025. All Rights Reserved by MedPath